Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...

Arrowhead secured a $500 million deal with Sarepta, including a $325 million stock purchase and potential milestone payments, boosting its financial stability. Arrowhead's NDA for plozasiran ...

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...

Q4 2024 Earnings Call Transcript November 26, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Needham lowered the firm’s price target on Sarepta (SRPT) to $202 from $205 and keeps a Buy rating on the shares. The deal with Arrowhead (ARWR) offers platform diversification with clear long-term ...

Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...

The adjustment follows Arrowhead's fourth fiscal quarter 2025 update, which highlighted a significant collaboration deal with Sarepta . The deal is viewed positively for its potential to transform ...

The adjustment follows Arrowhead's fourth fiscal quarter 2025 update, which highlighted a significant collaboration deal with Sarepta . The deal is viewed positively for its potential to transform ...

Bernstein lowered the firm’s price target on Arrowhead (ARWR ... primarily on the large collaboration deal announced with Sarepta (SRPT) (SPRT) and implications for its own strategy going ...